Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome  by Rosa, Gian Marco et al.
E U RO P E AN URO LOGY 6 9 ( 2 0 1 6 ) 3 1 1 – 3 2 3
ava i lable at www.sciencedirect .com
journal homepage: www.europeanurology.comReview – Voiding Dysfunction
Cardiovascular Safety of b3-adrenoceptor Agonists for the
Treatment of Patients with Overactive Bladder SyndromeGian Marco Rosa a, Simone Ferrero a, Victor W. Nitti b, Adrian Wagg c, Tahir Saleemd,
Christopher R. Chapple e,*
a IRCCS AOU San Martino – University of Genoa, Genoa, Italy; bDepartment of Urology, NYU Langone Medical Center, New York, NY, USA; cDivision of
Geriatric Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; dAstellas Pharma Europe Ltd, Chertsey, Surrey, UK;
eDepartment of Urology, Royal Hallamshire Hospital, Sheffield, UKArticle info
Article history:
Accepted September 4, 2015
Associate Editor:
Christian Gratzke
Keywords:
b3-Adrenoceptor agonist
Cardiovascular
Overactive bladder
Safety
Abstract
Context: Mirabegron, the first b3-adrenoceptor agonist in clinical practice, is approved
for treatment of overactive bladder (OAB) syndrome symptoms. Because b3-adreno-
ceptors are expressed in cardiovascular (CV) tissues, there are concerns that OAB
treatment with b3-adrenoceptor agonists may affect the heart and vasculature.
Objective: To provide a summary of CV effects of b3-adrenoceptor agonists in clinical
studies.
Evidence acquisition: A systematic literature search from inception until November
2014 was performed on studies in PubMed and Medline.
Evidence synthesis: Twenty papers, published between 1994 and 2014, were identiﬁed:
mirabegron (16), solabegron (2), AK-677 (1), and BRL35135 (1). More detailed CV data
from mirabegron studies were available in online regulatory documents ﬁled with the
US Food and Drug Administration and the UK National Institute for Health and Care
Excellence.
Conclusions: The CV safety of mirabegron appears to be acceptable at therapeutic doses
and comparable with that of antimuscarinic agents, currently ﬁrst-line therapy for OAB.
Patient summary: In this review we looked at the cardiovascular (CV) effects of b3-
adrenoceptor agonists used for the treatment of overactive bladder (OAB). The CV safety
of mirabegron (the only clinically approved b3-adrenoceptor agonist) appears to be
acceptable at therapeutic doses and comparable with that of antimuscarinic agents, the
current ﬁrst-line therapy for OAB.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).* Corresponding author. Department of Urology, Royal Hallamshire Hospital, Glossop Road, Shefﬁeld,
S10 2JF, UK Tel. +44 0114 279 7841; Fax: +44 0114 271 1901.
ple@shef.ac.uk (C.R. Chapple).E-mail address: c.r.chap1. Introduction
Overactive bladder (OAB) syndrome is estimated to affect
>400 million people worldwide [1]. Prevalence increases
with age, affecting approximately 15% aged 65 yr [2] and
30–40% 75 yr [3]. Many patients with OAB have multiple
http://dx.doi.org/10.1016/j.eururo.2015.09.007
0302-2838/# 2015 European Association of Urology. Published by Elsevier
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).concomitant cardiovascular (CV) comorbidities, such as
hypertension, diabetes, and heart failure [4–6]. In this
context, the CV safety of OABpharmacotherapy is important.
Antimuscarinic agents have been the mainstay of OAB
treatment [7] and are generally considered to have good
CV safety [8]. Although rare, CV adverse events (AEs) ofB.V. This is an open access article under the CC
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 3 1 1 – 3 2 3312antimuscarinics administered to patients with OAB are
noteworthy and may be clinically important. The most
common cardiac AEs associated with antimuscarinics are
increases in QT interval prolongation and heart rate (HR)
related to fesoterodine, propiverine, tolterodine, solifena-
cin, and trospium use [8]. More important, antimuscarinic
efficacy is limited by poor levels of persistence, often due to
undesirable AEs such as dry mouth, constipation, and
blurred vision [8].
Advances in the understanding of OAB pathophysiology
have identified three b-adrenoceptor subtypes—b1, b2, and
b3—in the bladder detrusor muscle and urothelium
[9,10]. In human bladder, b3-adrenoceptors account for
97% of total b-adrenoceptor messenger RNA [11], and they
are thought to be the main subtype mediating relaxation of
detrusor smooth muscle during the storage phase
[12]. However, all three adrenoceptor subtypes are
expressed in the CV system, leading to potential concerns
about the CV effects of b-adrenoceptor agonists. Both b1 and
b3 receptors are expressed in the heart; b1-mediated effects
increase HR and force of contraction; compounds with
relatively limited b3-adrenoceptor agonist selectivity and
activity trigger positive inotropic effects in human atrial
tissue and negative inotropic effects in ventricular tissue
[13]. In addition, b2-adrenoceptors are located in vascular
smooth muscle, mediating vasodilation (especially in
arteriolar beds in extremities) [14].
Mirabegron, the first b3-adrenoceptor agonist to enter
clinical practice, is approved at doses of 25 and 50mg for the
treatment of OAB symptoms; in vitro, it shows substantially
higher (150- and 33-fold) affinity for b3-adrenoceptors
versus that for b1- and b2-adrenoceptors, respectively
[15]. Other b3-adrenoceptor agonists have reported clinical
(solabegron [16], TAK-677 [17,18]) or preclinical (ritobegron
[19,20], TRK-380 [21], BRL35135 [22]) results.
Because b3-adrenoceptors are also expressed in CV
tissues, there are concerns that OAB treatment with b3-
adrenoceptor agonists may have ‘‘off-target’’ effects on
regulation of the heart and vasculature [23]. This article
provides a summary of CV effects of b3-adrenoceptor
agonists in clinical studies.
2. Evidence acquisition
A systematic literature search was performed on the CV
effects of b3-adrenoceptor agonists in the PubMed and
Medline databases from inception until November
2014. The following text word and Medical Subject Head-
ings terms (mirabegron OR solabegron OR ritobegron OR
TAK677 OR BRL35135) AND clinical trial[ptyp] AND
English[lang] were used to identify suitable randomized
controlled trials. We applied screening criteria including CV
end points—Antiplatelet Trialists’ Collaboration/Major Ad-
verse CV Events (APTC/MACE), thorough QT (TQT), vital
signs, electrocardiogram (ECG) parameters—to 160 identi-
fied references (Supplementary Fig. 1). Supplementary
Table 1 presents inclusion and exclusion criteria. Two
independent reviewers screened the full text of the
remaining articles and identified 20 that met inclusioncriteria. Disagreements were resolved by discussion be-
tween reviewers. To ascertain the validity of eligible studies
and minimize risk of bias, the reviewers determined the
adequacy of study characteristics, although no validated
quality assessments were performed. No trials were
excluded at this point of the selection process.
Additional information was identified from publicly
available regulatory documents filed with the US Food and
Drug Administration (FDA) and the National Institute for
Health and Care Excellence (NICE) in the United Kingdom.
3. Evidence synthesis
A total of 20 papers, published between 1994 and 2014,
were identified; 16 focused onmirabegron, 2 on solabegron,
1 on TAK-677, and 1 on BRL35135 (Supplementary Table 2).
Table 1 provides a design overview for mirabegron phase
2 and 3 studies and CV exclusion criteria. Only limited
clinical information exists on solabegron, TAK-677, and
BRL35135. More detailed CV data from mirabegron studies
identified in the literature search was available in online
regulatory documents filed with the FDA and NICE.
3.1. Statistical analysis
Categorical variables are given using frequencies and/or
percentages. Continuous variables are given using mean,
standard deviation, and overall range; means with standard
error (SE) were used when the former was unavailable.
Statistical methods used to analyze change from baseline to
final visit in vital signs, treatment differences, and to
estimate relative risks versus placebo are described in
Supplement 1.
3.2. Overview of cardiovascular effects: analysis of data from
12-wk and 1-yr clinical trials
As the only clinically approved agent in the class, the bulk of
the available information on the CV effects of b3-adreno-
ceptor agonists is derived from the mirabegron clinical trial
program. Mirabegron’s CV safety was analyzed in a detailed
prospective analysis of the pooled populations of three 12-
wk phase 3 trials (046 [NCT00689104], 047 [NCT00662909],
and 074 [NCT00912964]) [24] and separately in a 1-yr
phase 3 trial (049 [NCT0688688]) [25]. These studies
enrolled men and women aged 18 yr with OAB symptoms
(Table 2). Data from placebo and mirabegron 50 mg arms of
studies 046, 047, and 074 were pooled, and data from the
mirabegron 100 mg arms of studies 046 and 047 were
pooled. Only study 074 included a mirabegron 25 mg arm.
CV-related events of interest were hypertension, corrected
QT (QTc) prolongation, and cardiac arrhythmia (including
atrial fibrillation and tachycardia). Overall, 0.5–1.9% of
patients had a history of atrial fibrillation/atrial flutter
(Table 2). Supplementary Table 3 provides an overview of
CV data from these studies. Of note, the pooled studies used
a consistent rigorous definition for defining the AE of
hypertension or tachycardia. A hypertension AE was
defined as average systolic blood pressure (SBP)
Table 1 – Summary of mirabegron phase 2 and 3 trials
Study
number
Patients
enrolled,
n
Patients
randomized,
n
Mirabegron
dose
Placebo
control
Active
comparator
Study duration,
double-blind
treatment
period
CV exclusion criteria
008 314 262 100 or 150 mg
twice daily*
Yes Tolterodine
4 mg ER
once daily
4 wk Any clinically signiﬁcant CV complication including CVA,
recent MI, and uncontrolled hypertension, indicated by a
sitting SBP 180 mm Hg and/or DBP 110 mm Hg
044 1108 928 25, 50, 100,
or 200 mg
once daily
Yes Tolterodine
4 mg ER
once daily
12 wk Clinically signiﬁcant CV or cerebrovascular diseases within
6 mo prior to placebo run-in, such as MI, uncontrolled
angina, signiﬁcant ventricular arrhythmias, sinus
tachycardia, heart failure (NYHA class II/IV), orthostatic
hypotension, stroke, and uncontrolled hypertension,
indicated by a sitting SBP 160 mm Hg and/or DBP
100 mm Hg
Patients with a HR <45 and >100
ECG on visit 1 showing a QTc interval >470 ms, patients
with risk factors for torsades de pointes, hypokalemia,
familial long QT syndrome, patients receiving comedication
with QT-prolonging drugs
Any other clinically signiﬁcant abnormal ECG that in the
opinion of the investigator makes the patient unsuitable for
the study
046 2336 1987 50 or 100 mg
once daily
Yes Tolterodine
4 mg ER
once daily
12 wk Severe hypertension, deﬁned as a sitting average SBP
180 mm Hg and/or average DBP 110 mm Hg
A clinically signiﬁcant abnormal ECG that in the opinion of
the investigator made the patient unsuitable for the study
047 2149 1329 50 or 100 mg
once daily
Yes No 12 wk As for study 046
074 2030 1306 25 or 50 mg
once daily
Yes No 12 wk As for study 046
049 2801 2444 50 or 100 mg
once daily
No Tolterodine
4 mg ER
once daily
12 mo As for study 046
048 1332 1139 50 mg
once daily
Yes Tolterodine
4 mg ER
once daily
12 wk Acute cerebrovascular disease, serious CV disease (eg, MI,
cardiac insufﬁciency, uncontrolled angina pectoris, or
serious arrhythmias) or clinically signiﬁcant orthostatic
hypotension within 24 wk prior to initiating the run-in
period
Uncontrolled hypertension (sitting SBP 180 mm Hg or
DBP 110 mm Hg when BP was measured prior to run-in or
at baseline
PR 110 bpm or <50 bpm when measured prior to run-in
ECG abnormalities measured prior to the run-in period that
caused the ECG readers to deem the patient unsuitable for
the study
090 1506 1126 50 mg
once daily
Yes Tolterodine
4 mg ER
once daily
12 wk Patients who experienced acute cerebrovascular disorder,
serious CV disorder (eg, MI, cardiac failure, uncontrolled
angina, serious arrhythmia) or clinically signiﬁcant
orthostatic hypotension within 24 wk before initiation of
the run-in period
Patients with uncontrolled hypertension (indicated by a
sitting SBP 180 mm Hg or DBP 110 mm Hg measured
prior to run-in)
Patients with a pulse rate 10 bpm or <50 bpm or any
clinically signiﬁcant abnormal ECG as judged by the
cardiologist prior to run-in
Patients with clinically signiﬁcant, serious cardiac disease
CV = cardiovascular; CVA = cerebrovascular accident; DBP = diastolic blood pressure; ECG = electrocardiogram; ER = extended release; HR = heart rate;
MI = myocardial infarction; NYHA = New York Heart Association functional classiﬁcation; PR = pulse rate; SBP = systolic blood pressure.
* Immediate release formulation.
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Table 2 – Patient demographics and baseline characteristics by treatment group: pooled 12-wk populations (studies 046, 047, and 074) and 1-yr population (safety analysis set)
Pooled* 12-wk phase 3 studies (046, 047, and 074) 1-yr phase 3 study (049)
Placebo
(n = 1380)
Mirabegron Tolterodine ER 4 mg
(n = 495)
Mirabegron Tolterodine ER 4 mg
(n = 812)
25 mg
(n = 432)
50 mg
(n = 1375)
100 mg
(n = 929)
50 mg
(n = 812)
100 mg
(n = 820)
Sex, n (%)
Female 1002 (73) 293 (68) 982 (71) 675 (73) 361 (73) 602 (74) 608 (74) 600 (74)
Male 378 (27) 139 (32) 393 (29) 254 (27) 134 (27) 210 (26) 212 (26) 212 (26)
Age, yr
Mean (SD) 59.2 (13.3) 58.5 (12.9) 59.5 (12.7) 59.9 (13.0) 59.1 (12.9) 59.2 (12.6) 60.1 (11.9) 59.6 (12.5)
Range 20–95 22–85 21–91 19–90 18–83 21–87 22–86 21–87
Race, n (%)
White 1274 (92) 394 (91) 1279 (93) 873 (94) 490 (99) 778 (96) 774 (94) 780 (96)
Black 84 (6.1) 32 (7.4) 66 (4.8) 38 (4.1) 3 (0.6) 22 (2.7) 30 (3.7) 20 (2.5)
Asian 13 (0.9) 5 (1.2) 19 (1.4) 10 (1.1) 2 (0.4) 8 (1.0) 8 (1.0) 5 (0.6)
Other 9 (0.7) 1 (0.2) 11 (0.8) 8 (0.9) 0 4 (0.5) 8 (1.0) 7 (0.9)
BMI, kg/m2
Mean (SD) 29.1 (6.3) 29.8 (6.5) 29.0 (6.1) 29.0 (6.1) 27.8 (5.0) 29.0 (6.3) 28.8 (6.0) 28.5 (5.7)
Range 16–58 18–58 16–60 16–63 18–49 16–58 19–60 16–53
Hypertension status 1 at baseline, n (%)**,y
Normotensive 857 (62) 250 (58) 873 (64) 555 (60) 300 (61) 488 (60) 509 (62) 478 (59)
Hypertensive 523 (38) 182 (42) 502 (37) 374 (40) 195 (39) 324 (40) 311 (38) 334 (41)
Hypertension status 2 at baseline, n (%)**,z
Normal 455 (33) 101 (23) 432 (31) 317 (34) 133 (27) 226 (28) 236 (29)
(n = 819)
229 (28)
Prehypertension 637 (46) 219 (51) 665 (48) 445 (48) 259 (52.3) 431 (53) 426 (52) 411 (51)
Stage 1 hypertension 255 (19) 96 (22.2) 228 (16.6) 142 (15.3) 87 (17.6) 132 (16.3) 139 (17.0) 159 (19.6)
Stage 2 hypertension 33 (2.4) 16 (3.7) 50 (3.6) 25 (2.7) 16 (3.2) 23 (2.8) 18 (2.2) 13 (1.6)
History of tachyarrhythmia, n (%) 28 (2.0) 7 (1.6) 34 (2.5) 15 (1.6) 8 (1.6) 17 (2.1) 20 (2.4) 20 (2.5)
History of atrial ﬁbrillation/atrial ﬂutter, n (%) 16 (1.2) 6 (1.4) 26 (1.9) 11 (1.2) 5 (1.0) 4 (0.5) 15 (1.8) 14 (1.7)
Use of systemic b-blockers at baseline, n (%) 214 (16) 77 (18) 191 (14) 166 (18) 91 (18) 137 (17) 128 (16) 134 (17)
Baseline QTcF, n (%)
450 ms 1295 (96)
(n = 1346)
419 (97) 1294 (96)
(n = 1350)
861 (96)
(n = 901)
459 (97)
(n = 473)
779 (97)
(n = 804)
787 (97)
(n = 813)
769 (96)
(n = 801)
>450 ms 51 (3.8) 13 (3.0) 56 (4.1) 40 (4.4) 14 (3.0) 25 (3.1) 26 (3.2) 32 (4.0)
History of hyperlipidemia, n (%) 332 (24) 117 (27) 335 (24) 207 (22) 75 (15) 181 (22) 158 (19) 161 (20)
History of atherosclerotic disease, n (%) 147 (11) 42 (10) 144 (11) 112 (12) 63 (13) 67 (8.3) 90 (11) 92 (11)
History of cardiac failure, n (%) 6 (0.4) 1 (0.2) 3 (0.2) 7 (0.8) 4 (0.8) 2 (0.2) 4 (0.5) 3 (0.4)
BMI = body mass index; ER = extended release; QTcF = QT interval corrected for heart rate using Fridericia formula; SD = standard deviation.
* Because the mirabegron 25 mg dose was used only in study 074 and the tolterodine (active control arm) only in study 046, these data are not pooled.
** Baseline hypertension status 1 based on medical history and medication history.
y The hypertensive population comprised all patients who had a medical history of hypertension and received concurrent antihypertensive treatment at the screening visit; the normotensive population comprised all
patients who did not meet the deﬁnition of hypertensive.
z Baseline hypertension status 2 based on baseline diary systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements were SBP <120 mm Hg and DBP <80 mm Hg = normal; SBP 120–139 mm Hg or
DBP 80–89 mm Hg = prehypertension; SBP 140–159 mm Hg or DBP 90–99 mm Hg = stage 1 hypertension; SBP 160 mm Hg or DBP 100 mm Hg = stage 2 hypertension.
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90 mm Hg at two consecutive visits after baseline for
normotensive patients; average SBP increased 20 mm Hg
and/or average DBP increased 10 mm Hg from baseline at
two consecutive visits in patients with hypertension at
baseline or at initiation/increase in antihypertensive
medication. Tachycardia was reported as an AE if the
average daytime (AM) and nighttime (PM) resting pulse rate
(PR) measured by the patient over 3 d was >100 beats per
minute (bpm). An independent CV committee adjudicated
serious potential CV-related AEs and deaths for all
mirabegron studies using the categorization of APTC/MACE
or non-APTC/MACE [26].
3.2.1. APTC/MACE or non-APTC/MACE
APTC/MACE events have become the standard so-called
hard end point for assessing the CV effects of drugs. In the
pooled 12-wk and 1-yr mirabegron studies, APTC/MACE
events were not increased in the mirabegron population for
any dose and were comparable with placebo [27]. In the
1-yr study, APTC/MACE events occurred in 0.7% of patients
in the mirabegron 50 mg group (n = 812): nonfatal stroke
(three patients), nonfatal myocardial infarction (two
patients), and CV death (one patient) (Table 3). Such events
occurred in 0.5% of patients in the tolterodine extended-
release (ER) group (n = 812): CV death (two patients),
nonfatal myocardial infarction (one patient), and nonfatal
stroke (one patient).
Among all mirabegron patients in studies 044, 045, 046,
047, 048, and 074, there was no evidence of risk for the
occurrence of APTC/MACE events versus placebo (relative
risk [RR] for all mirabegron doses vs placebo events: 0.24;
95% confidence interval [CI], 0.02–1.69]). Similarly, therewas
noevidenceof risk in the1-yr studyversus tolterodine (RR for
mirabegron 50mg vs tolterodine: 0.75; 95% CI, 0.18–3.60),
although a large increase in risk cannot be discounted [27].
3.2.2. Blood pressure
Hypertension was the most commonly reported treatment-
emergent adverse event (TEAE) across the OAB phase
3 population, occurring in approximately 8.7% of patients
receiving mirabegron 50 mg versus 8.5% on placebo in the
pooled 12-wk studies (Table 3); however, themean increase
in SBP/DBP associated with mirabegron 50 mg was 1 mm
Hg in OAB patients and was reversible upon treatment
discontinuation. Specifically, for pooled 12-wk studies,
adjusted mean difference versus placebo for change from
baseline to week 12/final visit in SBP was 0.6 (SE: 0.35) and
0.5 (SE: 0.36) for AM and PMmeasurements, respectively; and
for DBP was 0.4 (SE: 0.22) and 0.4 (SE: 0.23) for AM and PM
measurements, respectively. Hypertension incidence de-
creased as mirabegron dose increased from 25 to 100 mg
(Table 3) and was similar between mirabegron 50 mg and
placebo in pooled 12-wk studies and between mirabegron
and tolterodine in the 1-yr study. More detailed accounts of
changes in vital signs are available in regulatory documents
(Supplementary Fig. 2 and 3) [27]. Increases from baseline
in SBP/DBP were generally similar across placebo, mirabe-
gron, and tolterodine groups (Tables 4 and 5). Changes frombaseline in blood pressure (BP) and PR when analyzed in
patients with stage 1 and 2 hypertension were consistent
with those in the total patient population (Supplementary
Fig. 4a and 4b). Subgroup analyses by age group showed
very similar mean changes for SBP/DBP across age groups,
with larger PR changes in younger patients in some analyses
(Supplementary Fig. 4c and 4d). Changes in vital signs for
studies 046, 047, and 074 individually are shown in
Supplementary Table 4–6.
In a study in a mixed non-Japanese Asian OAB popula-
tion, hypertension TEAEs occurredwith an incidence of 0.5%
and 0.8% in the mirabegron 50 mg and tolterodine ER 4 mg
groups, respectively [28]. Adjusted mean differences from
placebo in SBP and DBP upon awakening were similar in the
mirabegron 50 mg and tolterodine groups (0.22 [95% CI,
1.38 to 1.82] and 0.28 [95% CI,1.33 to 1.88], respectively)
[28]. There were also no clinically relevant effects on SBP/
DBP or ECG findings in OAB patients in the proof-of-concept,
dose-finding, or Japanese phase 3 studies [29–31].
In a QT/QTc study in healthy volunteers, maximummean
increases in SBP/DBP with mirabegron 50 mg were approx-
imately 4.0/1.6 mmHggreater thanplacebo [32,33].Modest
BP increases were observed in a multiple-dose pharmaco-
kinetic study thatwas not clearly correlatedwith increasing
mirabegron dose (50–300 mg). No participant showed a
positive orthostatic stress test [34]. In a study in healthy
Japanese participants, therewere dose-dependent increases
in SBP at 3–6 h after dose, but these were possibly due to
circadian rhythm because of the timing of the initial dose (9
AM). Therewere no changes inmeanDBP for anymirabegron
dose (50–400 mg) [35].
Because a1-adrenoceptor antagonists such as tamsulosin
are associated with CV AEs and may be used concomitantly
withmirabegron inmenwith lower urinary tract symptoms
characteristic of benign prostatic hyperplasia, potential
pharmacokinetic and CV interactions upon add-on of
mirabegron 100 mg or tamsulosin 0.4 mg to existing
tamsulosin or mirabegron monotherapy were evaluated
[36]. In 48 healthy men aged 44–72 yr, tamsulosin and
mirabegron cotherapy did not cause clinically relevant
changes in assessed CV parameters up to 12 h after dose
[36].
3.2.2.1. Solabegron. Other than mirabegron, solabegron is the
only b3-adrenoceptor agonist tested in phase 2 clinical trials
for OAB treatment [37]. In a randomized double-blind
proof-of-concept study in women with OAB, hypertension
was reported by 2 of 88 participants (2.3%) receiving 8wk of
twice daily solabegron 50 mg and 3 of 85 participants (3.5%)
receiving twice daily 125 mg solabegron. However, com-
parisons with other agents are difficult because exact
criteria for classification of hypertension were not reported.
In 24-h ambulatory BP monitoring, solabegron did not
induce significant changes from baseline to week 8 in SBP
(adjusted mean difference from placebo: –1.9, 1.3 mm Hg),
DBP (–2.1; –0.1 mmHg), or HR (0.8; 1.1 bpm) for the 50 mg
and 125 mg groups, respectively. A similar lack of effect on
vital signs was noted during office visits, and there were no
noteworthy changes in ECG parameters ormorphology [37].
Table 3 – Summary of cardiovascular and electrocardiogram safety analysis set (SAF): pooled 12-wk populations (studies 046, 047, and 074) and 1-yr population (SAF)
Pooled* 12-wk phase 3 studies (046, 047, and 074) 1-yr phase 3 study (049)
Placebo
(n = 1380)
Mirabegron Tolterodine ER 4 mg
(n = 495)
Mirabegron Tolterodine ER 4 mg
(n = 812)
25 mg
(n = 432)
50 mg
(n = 1375)
100 mg
(n = 929)
50 mg
(n = 812)
100 mg
(n = 820)
CV events
Incidence, n (%), of APTC/MACE 4 (0.3) 0 0 0 1 (0.2) 6 (0.7) 0 4 (0.5)
Relative risk** of APTC/MACE (95% CI) – NE NE NE – 1.50 (0.35–7.3) NE –
Incidence, n (%), of:
Hypertension TEAEs 117 (8.5) 52 (12) 120 (8.7) 58 (6.2) 48 (9.7) 89 (11) 83 (10) 86 (11)
Hypertension SAEs 0 0 1 (0.1) 0 1 (0.2) 1 (0.1) 1 (0.1) 0
Discontinuations due to hypertension TEAEs 3 (0.2) 2 (0.5) 5 (0.4) 4 (0.4) 1 (0.2) 4 (0.5) 2 (0.2) 4 (0.5)
Relative risk** of hypertension TEAE (95% CI) – 1.3 (0.86–1.8) [11_TD$DIFF] .0 (0.79–1.3) [12_TD$DIFF]0.78 (0.56–1.1) [13_TD$DIFF]– 1.0 (0.77–1.4) [14_TD$DIFF]0.94 (0.70–1.3) [15_TD$DIFF]–
Incidence, n (%), of:
Tachycardia overally 43 (3.1) 21 (4.9) 52 (3.8) 43 (4.6) 16 (3.2) 25 (3.1) 49 (6.0) 53 (6.5)
Tachycardia TEAEs 9 (0.7) 10 (2.3) 18 (1.3) 7 (0.8) 3 (0.6) 10 (1.2) 19 (2.3) 26 (3.2)
Tachycardia SAEs 0 0 0 1 (0.1) 0 0 0 0
Discontinuations due to tachycardia TEAEs 0 1 (0.2) 2 (0.1) 2 (0.2) 1 (0.2) 0 0 0
ECG QT prolongation events 0 0 0 0 2 (0.4) 3 (0.4) 2 (0.2) 3 (0.4)
ECG data
QTcF interval
Patients, n (%), meeting threshold criteria, maximum value of:
>450 ms 44 (3.5) 14 (3.4) 32 (2.6) 27 (3.2) 18 (4.1) 36 (4.9) 29 (3.9) 32 (4.4)
>480 ms 3 (0.2) 0 3 (0.2) 5 (0.6) 3 (0.7) 5 (0.7) 2 (0.3) 6 (0.8)
>500 ms 1 (0.1) 0 0 1 (0.1) 1 (0.2) 2 (0.3) 1 (0.1) 1 (0.1)
Patients, n (%), with increase from baseline of:
30 ms 44 (3.6) 9 (2.2) 53 (4.3) 24 (2.9) 25 (5.9) 76 (10) 67 (9.0) 77 (11)
60 ms 2 (0.2) 1 (0.2) 1 (0.1) 2 (0.2) 2 (0.5) 3 (0.4) 3 (0.4) 3 (0.4)
APTC/MACE = Antiplatelet Trialists’ Collaboration/Major Adverse CV Event; CI = conﬁdence interval; ECG = electrocardiogram; ER = extended release; NE = not evaluated due to insufﬁcient data; QTcF = QT interval
corrected for heart rate using Fridericia formula; SAE = serious adverse event; SAF = safety analysis set: all randomized patients who took one dose or more of double-blind study drug; TEAE = treatment-emergent adverse
event.
* Because the mirabegron 25 mg dose was used only in study 074 and the tolterodine (active control arm) only in study 046, these data are not pooled.
** Relative risk (RR) is versus placebo in pooled analysis and versus tolterodine in study 049; RR of hypertension estimated using hazard ratios and 95% CIs from a proportional hazards model (stratiﬁed by study in the
pooled analysis); RR of APTC/MACE estimated using odds ratios and exact 95% CIs.
y Based on TEAE and/or observations of pulse rate 100 bpm captured by patient diary.
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Table 4 – Summary of changes from baseline to final visit in vital signs measured by patient’s diary: pooled 12-wk populations (studies 046, 047, and 074) [24]
Placebo
(n = 1380)
Mirabegron 25 mg
(n = 432)
Mirabegron 50 mg
(n = 1375)
Mirabegron 100 mg
(n = 929)
Tolterodine ER 4 mg
(n = 495)
AM PM AM PM AM PM AM PM AM PM
BP, mm Hg
SBP
n 1329 1326 410 410 1327 1327 891 890 476 476
Baseline, mean (SE) 125.9 (0.47) 125.0 (0.41) 129.2 (0.81) 129.0 (0.71) 126.4 (0.47) 125.6 (0.43) 125.0 (0.55) 123.7 (0.49) 128.2 (0.75) 127.4 (0.64)
Final visit, mean (SE) 126.2 (0.45) 125.7 (0.41) 128.8 (0.75) 128.3 (0.67) 127.2 (0.46) 126.6 (0.41) 125.6 (0.51) 125.2 (0.46) 128.4 (0.70) 127.9 (0.63)
Adjusted change from baseline,
mean (SE) (95% CI)*
0.2 (0.25)
(0.3 to 0.7)
0.6 (0.25)
(0.1–1.1)
0.3 (0.52)
(1.3 to 0.7)
0.5 (0.53)
(1.5 to 0.6)
0.8 (0.25)
(0.3–1.3)
1.1 (0.25)
(0.6–1.6)
0.6 (0.32)
(0.0 to 1.2)
1.4 (0.33)
(0.8–2.1)
0.1 (0.45)
(0.8 to 1.0)
0.5 (0.46)
(0.4 to 1.4)
Difference vs placebo,
mean (SE) (95% CI)**
– – 0.5 (0.57)
(1.6 to 0.6)
1.0 (0.58)
(2.2 to 0.1)
0.6 (0.35)
(0.1 to 1.3)
0.5 (0.36)
(0.2 to 1.2)
0.4 (0.41)
(0.4 to 1.2)
0.9 (0.42)
(0.1–1.7)
0.1 (0.52)
(1.1 to 1.0)
0.0 (0.53)
(1.1 to 1.0)
DBP
n 1329 1326 410 410 1327 1327 890 890 476 476
Baseline, mean (SE) 77.1 (0.26) 75.3 (0.23) 78.2 (0.48) 76.1 (0.46) 77.2 (0.25) 75.4 (0.24) 77.4 (0.30) 75.3 (0.28) 76.8 (0.40) 75.4 (0.38)
Final visit, mean (SE) 77.2 (0.25) 75.7 (0.24) 77.6 (0.43) 75.7 (0.42) 77.6 (0.24) 76.2 (0.24) 77.7 (0.28) 76.3 (0.28) 77.7 (0.39) 76.6 (0.36)
Adjusted change from baseline,
mean (SE) (95% CI)*
0.0 (0.16)
(0.3 to 0.3)
0.4 (0.16)
(0.1–0.7)
0.1 (0.33)
(0.8 to 0.5)
0.1 (0.34)
(0.6 to 0.7)
0.4 (0.16)
(0.1–0.7)
0.7 (0.16)
(0.4–1.1)
0.2 (0.21)
(0.2 to 0.6)
0.9 (0.21)
(0.5–1.3)
0.8 (0.29)
(0.2–1.3)
1.4 (0.30)
(0.8–2.0)
Difference vs placebo,
mean (SE) (95% CI)**
– – 0.1 (0.37)
(0.9 to 0.6)
0.3 (0.37)
(1.0 to 0.4)
0.4 (0.22)
(0.1 to 0.8)
0.4 (0.23)
(0.1 to 0.8)
0.2 (0.26)
(0.3 to 0.7)
0.5 (0.27)
(0.0 to 1.0)
0.7 (0.33)
(0.1–1.4)
1.0 (0.34)
(0.4–1.7)
PR, bpm
n 1329 1326 410 410 1327 1327 891 890 476 476
Baseline, mean (SE) 70.5 (0.28) 75.3 (0.29) 71.0 (0.50) 75.5 (0.51) 70.4 (0.28) 74.9 (0.28) 70.4 (0.34) 74.4 (0.34) 69.8 (0.44) 73.9 (0.45)
Final visit, mean (SE) 70.9 (0.29) 74.7 (0.29) 71.7 (0.52) 75.3 (0.53) 71.8 (0.29) 75.5 (0.28) 72.9 (0.34) 76.5 (0.34) 71.4 (0.44) 76.0 (0.45)
Adjusted change from baseline,
mean (SE) (95% CI)*
0.4 (0.17)
(0.1–0.8)
0.4 (0.18)
(0.8 to 0.1)
1.3 (0.36)
(0.6–2.0)
0.2 (0.37)
(0.6 to 0.9)
1.4 (0.17)
(1.1–1.8)
0.6 (0.18)
(0.2–0.9)
2.3 (0.22)
(1.9–2.8)
1.9 (0.23)
(1.4–2.3)
1.4 (0.31)
(0.8–2.0)
1.7 (0.32)
(1.1–2.3)
Difference vs placebo,
mean (SE) (95% CI)**
– – 0.9 (0.40)
(0.1–1.6)
0.6 (0.41)
(0.2 to 1.4)
1.0 (0.24)
(0.5–1.5)
1.0 (0.25)
(0.5–1.5)
1.9 (0.28)
(1.3–2.5)
2.3 (0.29)
(1.7–2.9)
1.0 (0.36)
(0.3–1.7)
2.1 (0.37)
(1.4–2.8)
AM = daytime; BP = blood pressure; CI = conﬁdence interval; DBP = diastolic blood pressure; ER = extended release; PM = nighttime; PR = pulse rate; SE = standard error; SBP = systolic blood pressure.
* Adjusted changes from baseline are generated from the analysis of covariance model with treatment group, gender, and study as ﬁxed factors and baseline as a covariate.
** Differences of the adjusted means are calculated by subtracting the adjusted mean of placebo from the adjusted mean of the treatment group.
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Table 5 – Summary of changes from baseline to final visit in vital signs measured by patient’s diary; 1-yr study
Mirabegron 50 mg
(n = 812)
Mirabegron 100 mg
(n = 820)
Tolterodine ER 4 mg
(n = 812)
AM PM AM PM AM PM
BP, mm Hg
SBP
n 791 789 802 802 793 793
Baseline, mean (SE) 126.7 (0.58) 126.4 (0.50) 125.9 (0.56) 125.7 (0.50) 126.8 (0.55) 126.3 (0.49)
Final visit, mean (SE) 126.9 (0.56) 126.0 (0.49) 126.4 (0.53) 126.0 (0.49) 126.3 (0.54) 126.3 (0.50)
Adjusted change from baseline,
mean (SE) (95% CI)*
0.2 (0.33) (0.4 to 0.9) 0.3 (0.33) (0.9 to 0.3) 0.4 (0.33) (0.2 to 1.1) 0.1 (0.32) (0.5 to 0.8) 0.5 (0.33) (1.1 to 0.2) 0.0 (0.33) (0.7 to 0.6)
DBP
n 791 789 802 802 793 793
Baseline, mean (SE) 77.6 (0.31) 76.2 (0.30) 77.2 (0.29) 75.9 (0.29) 77.6 (0.30) 76.1 (0.29)
Final visit, mean (SE) 77.3 (0.30) 76.2 (0.30) 77.6 (0.29) 76.1 (0.30) 77.6 (0.31) 76.7 (0.31)
Adjusted change from baseline,
mean (SE) (95% CI)*
0.3 (0.21) (0.7 to 0.1) 0.0 (0.21) (0.4 to 0.4) 0.4 (0.20) (0.0 to 0.8) 0.1 (0.21) (0.3 to 0.5) 0.1 (0.21) (0.3 to 0.5) 0.6 (0.21) (0.2–1.0)
PR, bpm
n 791 789 802 802 792 792
Baseline, mean (SE) 71.0 (0.36) 74.2 (0.36) 70.2 (0.37) 74.1 (0.37) 70.1 (0.35) 73.8 (0.36)
Final visit, mean (SE) 71.8 (0.34) 74.5 (0.35) 71.9 (0.35) 75.4 (0.36) 71.8 (0.37) 75.8 (0.36)
Adjusted change from baseline,
mean (SE) (95% CI)*
0.9 (0.23) (0.5–1.4) 0.4 (0.24) (0.1 to 0.8) 1.6 (0.22) (1.2–2.1) 1.3 (0.24) (0.8–1.7) 1.5 (0.22) (1.1–2.0) 1.9 (0.24) (1.4–2.4)
AM = daytime; BP = blood pressure; CI = conﬁdence interval; DBP = diastolic blood pressure; ER = extended release; PM = nighttime; PR = pulse rate; SBP = systolic blood pressure; SE = standard error.
* Adjusted changes from baseline are generated from the analysis of covariance model with previous study history, treatment group, gender, and geographic region as ﬁxed factors and baseline as a covariate.
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The potential for mirabegron to prolong QTc was investi-
gated in a TQT study, powered for each gender according to
International Conference on Harmonisation E14 guidance
(threshold of regulatory concern for proarrhythmia: an
upper bound of the one-sided 95% CI of 10 ms [38]). In a
randomized placebo- and active (moxifloxacin)-controlled,
parallel, crossover, heart-rate–corrected QT interval (QT/
QTc) study in 176 healthy men and 176 healthy women,
mirabegron 50 or 100 mg did not cause QTc prolongation
[32]. However, at a supratherapeutic dose (200 mg), the QTc
interval was prolonged in female participants (95% CI of QTc
of 13.44 ms, occurring at 5 h).
In the pooled 12-wk population, frequency of QTc
prolongation AEs was low (0.4%) and similar across
placebo, mirabegron, and tolterodine groups [24]. In the 1-
yr study, no consistent trends in ECG changes were
identified [25]. Categorical outliers in QT interval cor-
rected for HR using the Fridericia formula (QTcF) were low
across treatment groups (Table 3). As expected, due to
longer QTc intervals generally present in women, female
OAB patients had a higher frequency of maximum QTcF
values>450 ms versusmen in the pooled populations; this
was not the case in the 1-yr study [25,27]. The frequency of
QTcF change from baseline of 30 ms and <60 ms was
similar in both genders in the pooled populations, but it
was higher in women versus men in the 1-yr study. No
trends between genders were observed in other categori-
cal QTcF analyses [27]. In the non-Japanese Asian OAB
study, TEAEs of potential QTc prolongation occurred with
an incidence of 0.8%, 0.5%, and 1.1% in the placebo,
mirabegron 50 mg, and tolterodine ER 4-mg groups,
respectively. No patients on mirabegron 50 mg had
absolute QTcF interval values >480 ms or an increase in
QTcF intervals >60 ms [28].
3.3.1. Heart rate and palpitations
Because both b1- and b3-adrenoceptors may affect the rate
and/or force of contraction of the heart [39], direct effects on
these parameters were assessed in clinical trials of b3-
adrenoceptor agonists. In mirabegron-treated OAB patients
in the pooled 12-wk population, there were small dose-
dependent increases from baseline in adjusted mean
difference versus placebo for both AM and PM PR measure-
ments, reversible on treatment discontinuation [33]
(Table 4). However, the PR increase associated with
mirabegron 50 mg versus placebo was approximately
1 bpm and was comparable with tolterodine for AM
measures; mirabegron 50 mg was less than tolterodine
ER 4 mg for PM measures. In the 1-yr study, adjusted mean
change from baseline PR showed a small increase in each
group; but again this was similar in the mirabegron 100 mg
and tolterodine groups and less in the mirabegron 50-mg
group (Table 5) [25]. More detailed accounts of changes in
vital signs are available in regulatory documents (Supple-
mentary Fig. 2 and 3) [27].
In the proof-of-concept study, mirabegron immediate
release (IR) 150 mg twice daily caused a 5-bpm meanincrease from baseline in PR, but this was not associated
with a clinically significant increase in CV events such as
palpitations. The effects of mirabegron IR 100 mg twice
daily and tolterodine ER 4 mg once daily on PR (observed
increases of 0.7 to 1.4 bpm) were not clinically relevant
[31].
Although there was a small but significant (p < 0.05)
increase from baseline PR in the mirabegron 100 and
200 mg groups in study 044 (AM 2.2 and 4.7 bpm vs 0.5 bpm
for placebo; PM 2.7 and 4.6 bpm vs 0.04 bpm for placebo),
this did not appear to be associated with an increased
incidence of atrial fibrillation or palpitations, which was
comparablewith that seenwith tolterodine [29]. The AM and
PM PR increases from baseline for the mirabegron 25 mg
group (0.34 and 0.44 bpm, respectively) and 50 mg group
(1.64 and 1.12 bpm, respectively) were not statistically
significant versus placebo. Adjusted mean changes from
baseline in AM and PM PR seenwith tolterodinewere 1.50 and
2.50, respectively.
In the Japanese phase 3 study, PR increased by
approximately 2 bpm after 4-wk treatmentwithmirabegron
50 mg versus placebo and returned to baseline 2 wk after
treatment [30]. In thenon-JapaneseAsianOABstudy, forboth
the mirabegron 50mg and tolterodine ER 4 mg groups, the
adjusted mean difference from placebo in PR was larger 6 h
after dose (1.57 and 2.72, respectively) than on awakening
(1.12 and 0.75, respectively). Also, at 6 h after dose, the
adjusted mean difference from placebo in PR appeared
smaller in themirabegron50 mggroup (1.57bpm)versus the
tolterodine ER 4 mg group (2.72 bpm) [28].
In the pooled 12-wk population, the overall occurrence
of tachycardia events, either based on TEAE and/or
observations of PR 100 bpm captured by patient diary,
was <5% in each treatment group and comparable with
placebo and tolterodine (Table 3) [24]. In the 1-yr
population, 1.2% of patients on mirabegron 50 mg versus
3.2% of patients on tolterodine ER 4 mg reported tachycar-
dia TEAEs (Table 3), with one patient on mirabegron 50 mg
experiencing a third-degree atrioventricular block.
PR changes were more apparent for young healthy
volunteers than for OAB patients. In the QT/QTc healthy
volunteer study, mirabegron increased HR on ECG in a dose-
dependent manner 5–6 h after dose (maximum mean
increases from baseline vs placebo: 6.7, 11, and 17 bpm
for the 50-, 100-, and 200-mg dose groups, respectively)
[40]. In healthy Japanese subjects, increases in PR or
palpitations were only significant for the 400-mg group, in
which PR exceeding 100 bpm 4–6 h after dosing occurred in
three of six participants, one of whom developed palpita-
tions 3 h after dosing. PR tended to increase in a dose-
dependent manner 6 h after dose in the 200-mg and higher
dose groups versus placebo [35].
3.3.1.1. BRL35135. In a study in eight healthy men, BRL35135
produced significant increases in HR and SBP, and signifi-
cant decreases in DBP versus placebo. Most of these cardiac
effects were due to b2-adrenoceptor stimulation. It is
possible that a small but significant chronotropic effect was
b3 mediated [22].
Table 6 – Concomitant cardiovascular medications during the
double-blind period in mirabegron phase 3 studies
Pooled 12-wk
population (studies 046,
047, and 074)
n = 4611
1-yr population
(study 049)
n = 2444
ACE/ARB (%) 1311 (28) 714 (29)
b-Blockers (%)* 778 (17) 451 (19)
Calcium channel blockers (%) 552 (12) 317 (13)
Diuretics (%) 477 (10) 289 (12)
Lipid-lowering agents (%) 1317 (29) 631 (26)
Antithrombotics (%) 963 (21) 501 (21)
Antidiabetics (%) 409 (9) 217 (9)
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker.
* Of these, approximately 11–18% were nonselective (b1 and b2) b-blockers.
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In study 046, the incidence of cardiac arrhythmias was
higher in tolterodine- treated than in mirabegron- and
placebo-treated patients (Supplementary Table 7). Atrial
fibrillation of medical importance was reported for 1 of 494
(0.2%), 2 of 493 (0.4%), 2 of 496 (0.4%), and 5 of 495 (1.0%)
patients in the placebo, 50 mg mirabegron, 100 mg
mirabegron, and tolterodine ER 4 mg groups, respectively
[35]. In seven cases, atrial fibrillation was not present at
baseline. Arrhythmia was reported for 5 of 494 (1.0%), 11 of
493 (2.2%), 9 of 496 (1.8%), and 16 of 495 (3.2%), respectively
[41]. In the 1-yr study, arrhythmia was reported for 3.9%,
4.1%, and 6.0% in the mirabegron 50 mg, mirabegron
100 mg, and tolterodine ER 4 mg groups, respectively [25].
In study 047, arrhythmia TEAEs were reported for 4 of
453 (0.9%), 9 of 442 (2.0%), and 10 of 433 (2.3%) patients in
the placebo, 50 mg, and 100 mg mirabegron groups,
respectively. These events included tachycardia in 2 of
453 (0.4%), 6 of 442 (1.4%), and 3 of 433 (0.7%) patients in
the placebo, 50 mg, and 100 mg mirabegron groups, and
atrial fibrillation in 0, 1, (0.2%), and 2 (0.5%) patients,
respectively [42] (Supplementary Table 7). In the non-
Japanese Asian study, potential cardiac arrhythmia oc-
curred with an incidence of 5.5%, 3.0%, and 2.2% in the
placebo, mirabegron 50 mg, and tolterodine ER 4 mg
groups, respectively [28] (Supplementary Table 7). There
was no incidence of ventricular arrhythmia in any group.
3.4. Concomitant b-blocker use in clinical trials
There has been some concern that because mirabegron is a
b3-adrenoceptor agonist, its efficacymight be diminished in
those taking concomitant b-blockers. In total, 17% of the
mirabegron pooled 12-wk and 19% of the 1-yr population
reported concomitant b-blockers (Table 6); of these
approximately 11–18% were nonselective (b1 and b2) b-
blockers. Mirabegron 50 and 100 mg were effective in
reducing the mean number of incontinence episodes and
micturitions per 24 h from baseline to final visit regardless
of concomitant b-blocker treatment (Supplementary
Table 8). In OAB patients with and without concomitant
b-blockers, mirabegron was well tolerated, with a similar
tolerability profile across treatment groups.
Mirabegron is metabolized by cytochrome P450 (CYP)
3A4 [43] and to a minor extent by CYP2D6 in humans. The
CYP2D6 inhibitory potential of mirabegron was investigat-
ed by evaluating the effect of concomitant mirabegron on
metoprolol, a selective b1-adrenoceptor antagonist. Mir-
abegron did not affect CV responses to metoprolol
[44]. There are no data on rates of CV effects associated
with other concomitant b-blocker and mirabegron use on
PR and BP versus those not taking concomitant b-blockers.
3.5. Discussion
Mirabegron, the only clinically approved b3-adrenoceptor
agonist, provided the bulk of data identified in the
systematic literature search. Across the 12-wk phase
2 and 3 population, 8.4% of patients had a history ofatherosclerotic disease, 1.4% had a history of tachyarrhyth-
mia, 0.9% had atrial fibrillation/atrial flutter, and 0.3% had
cardiac failure, with CV-related intrinsic and extrinsic
factors generally comparable across treatment groups
(unpublished data). The mirabegron OAB trial population
is representative of the general OAB population with regard
to CV risk factors and concomitant therapy.
Articles have described CV comorbidities in OAB patients
who were gender and age matched to non-OAB populations
from the HealthCore Integrated Research Database (HIRD)
and the EPIC study. Hypertension and diabeteswere the two
most common CV comorbidities in the OAB population,
with prevalence rates significantly higher than in non-OAB
gender- and age-matched groups [4,6,27]. Supplementary
Table 9 shows baseline demographics and comorbidities
of OAB patients from these populations and from pooled
12-wk and 1-yr populations. The percentage of patients
with hypertension at baseline was higher in mirabegron
OAB studies (39% for pooled 12-wk population, 40% for
1-yr population, 27% for HIRD, 29% for EPIC) [4,6,27]. The
percentage of patients with diabetes at baseline in the
mirabegron studies (8.2% for pooled population, 7.7% for
1-yr population) was similar to that reported in OAB
populations fromHIRD (8.1%) and EPIC (8.9%). Mean patient
age was higher in the mirabegron pooled population
(59.4 yr) and 1-yr population (59.6 yr) versus OAB
populations from HIRD (50.8 yr) and EPIC (53.8 yr)
[27]. In addition, patients in pooled mirabegron studies
received many of the common concomitant medications
used tomanage these CV comorbidities (Table 6). Therefore,
the safety of mirabegronwas assessed in a study population
representative of the general OAB population and that
includes similar or greater prevalence of the two most
common CV comorbidities.
Across the OAB patient population in the pooled 12-wk
phase 3 population, mirabegron 50 mg was associated with
small increases in BP and PR versus placebo, of approxi-
mately 1 mm Hg and 1 bpm, respectively, which were
reversible upon treatment discontinuation. There was no
increase in rates of hypertension (as defined by study
criteria) associated with mirabegron treatment versus
either placebo or tolterodine [27], and a low proportion
E U RO P E AN URO L OGY 6 9 ( 2 0 1 6 ) 3 1 1 – 3 2 3 321(<5%) of patients experienced tachycardia AEs. Similar
results were observed withmirabegron 25 mg [27]. Of note,
the pooled 12-wk studies used a consistent, rigorous
definition for defining hypertension and tachycardia AEs
[27]. The protocol-prespecified definition for hypertension
AE was average SBP 140 mm Hg and/or average DBP
90 mm Hg at two consecutive visits after baseline for
normotensive patients; average SBP increased 20 mm Hg
and/or average DBP increased 10 mm Hg at two consecu-
tive visits in patients with hypertension at baseline or
initiation/increase in antihypertensive medication. There-
fore a proportion of the population was controlled
hypertensive patients. Data for patients in this pooled
population represent>935 000 individualmeasurements of
PR, SBP, and DBP; no other drug for OAB has been so
extensively investigated for CV safety.
Discrepancies between CV data from clinical trials in
OAB patients and the larger increases in HR observed in
healthy volunteer studies, who are generally younger, may
be due to a relatively higher sensitivity of the cardiac
response to b-adrenoceptor agonists in young healthy
volunteers [14]. Results of nonclinical and clinical pharma-
cology studies also support the explanation that modest
activation of b1-adrenoceptors could occur at high mirabe-
gron exposures, with potential for causing increases in PR
[27]. The change from baseline PR in clinical OAB
populations is similar or less than the change from baseline
PR following treatment with established antimuscarinics
for OAB, such as fesoterodine 4 or 8 mg (3–5 bpm increase)
[45], trospium 60 mg (3 bpm increase) [46], or tolterodine
ER 4 mg (1.0–2.1 bpm increase [27]). Small changes in vital
signs, predominantly PR, are not unprecedented for OAB
therapies and did not result in more CV AEs or APTC/MACE
events in mirabegron groups versus tolterodine.
4. Conclusions
The CV safety ofmirabegron, the only clinically available b3-
adrenoceptor agonist, appears to be good and comparable
with that of antimuscarinic agents, the current first-line
therapy for OAB. However, data on patients with poorly
controlled hypertension, arrhythmia, or cardiac heart
failure are currently missing because those patients were
excluded from previous studies. Further long-term data are
desirable, and a European longer term observational study
of mirabegron use is ongoing; this study may also allow
identification of risk factors for developing CV AEs. Until
research is performed specifically to study patients with
other significant CV risk factors, such as coronary heart
disease and cardiomyopathy, and those aged >80 yr,
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